Impact of the COVID-19 Pandemic on Cancer Screening Disparities from 2015 to 2023: Findings from the NSHAP Survey
By
Lahari Vuppaladhadiam
Kristen Wroblewski
Phil Schumm
Jasmin Tiro
Louise Hawkley
Martha McClintock
Elbert S. Huang
July 16, 2026
Clinical Scorecard: Impact of the COVID-19 Pandemic on Cancer Screening Disparities from 2015 to 2023: Findings from the NSHAP Survey
At a Glance
Category Detail
Condition Cancer Screening Disparities Key Mechanisms Impact of COVID-19 on healthcare access and changes in screening guidelines. Target Population Middle-aged and older adults, particularly those in marginalized communities. Care Setting Nationally representative longitudinal study.
Key Highlights
Cancer screening rates for breast and colorectal cancer increased from 1990 to 2020. Certain subpopulations, including Hispanic and Black individuals, have lower screening rates. COVID-19 pandemic led to significant delays in cancer screenings. US Preventive Services Task Force guidelines for CRC and prostate cancer screening changed during the study period. Longitudinal analysis utilized NSHAP data from 2015-2023. Guideline-Based Recommendations
Diagnosis
Screening for colorectal cancer recommended starting at age 45 as of 2021. Management
Consultation for prostate specific antigen (PSA) testing recommended for individuals aged 55-69. Monitoring & Follow-up
Past-year screening status assessed through surveys. Risks
Delays in screening may exacerbate health disparities in marginalized communities. Patient & Prescribing Data
Middle-aged and older adults, particularly those aged 50 and above.
Screening rates for colonoscopies, mammograms, and PSA testing were analyzed.
Clinical Best Practices
Encourage timely cancer screenings, especially in at-risk populations. Monitor changes in screening guidelines and adapt practices accordingly. Address socioeconomic and educational barriers to improve screening rates. Related Resources & Content
